Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Deficit (Details Textual)

v3.20.2
Shareholders' Deficit (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 02, 2020
USD ($)
shares
May 08, 2020
USD ($)
$ / shares
shares
Apr. 17, 2020
USD ($)
shares
Apr. 02, 2020
USD ($)
$ / shares
shares
Jan. 13, 2020
USD ($)
$ / shares
shares
Dec. 12, 2019
USD ($)
$ / shares
shares
Aug. 20, 2020
$ / shares
shares
Apr. 28, 2020
USD ($)
$ / shares
shares
Feb. 20, 2020
USD ($)
$ / shares
shares
Feb. 18, 2020
USD ($)
$ / shares
shares
Nov. 30, 2019
USD ($)
$ / shares
shares
Oct. 31, 2019
USD ($)
$ / shares
shares
Sep. 30, 2020
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
shares
Mar. 31, 2020
USD ($)
shares
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
shares
Dec. 31, 2019
USD ($)
$ / shares
shares
Shareholders' Deficit (Textual)                                      
Preferred Stock par value | $ / shares                         $ 0.10       $ 0.10   $ 0.10
Net of fees                                 $ 2,500    
Amortization of debt discount                                 424,001 $ 49,042  
Accrued interest                         $ 36,244       $ 36,244    
Common shares issued for debt conversion, shares | shares     203,125                           37,171,800    
Amount of common stock upon conversion                         86,944 $ 91,365          
Accrued dividends                         1,055       $ 1,055    
Stock-based compensation                                 366,825 1,845,834  
Interest expense                         274,966     $ 58,421 732,547 171,060  
Issuance of common shares for services, amount                         6,500 $ 50,000   50,000    
Stock-based professional fees                                 $ (69,917) (292,785)  
Common share exercise compensation, shares | shares                                 16,132,701    
Total unrecognized compensation expense related to unvested common shares                         $ 194,889       $ 194,889    
Weighted average period                                 1 year    
Cash proceeds from investor                                 $ 117,047    
Warrant exercise price reduced | $ / shares                         $ 0.01       $ 0.01    
Aggregate principal amount                                 $ 135,833
Convert of deferred compensation     $ 16,250                                
Exercise of stock options, value                                 19,185  
Recorded settlement expense                                    
Increase decrease in accounts payable                                 55,721 161,330  
Increase decrease in accrued expenses                                 88,771 51,097  
Shares issued for deferred compensation, description       the Company entered into two one-year advisory board agreements with two individuals for services to be rendered on the Company's medical advisory board. In connection with these advisory board agreements, the Company issued an aggregate of 500,000 restricted common shares of the Company to these advisory board members. These shares vest on April 1, 2021. These shares were valued at $20,000, or $0.04 per common share, based on contemporaneous common share sales by the Company. In connection with this consulting agreement, during the nine months ended September 30, 2020, accretion of stock-based consulting fees amounted to $10,000 and the remaining stock-based consulting fees of $10,000 shall be accreted over the remaining vesting period.                              
Conversion of principal balance                                 $ 152,285    
Stock option, description                                 The weighted average period over which stock-based compensation expense related to these options will be recognized is approximately 4 months.    
Accrued dividend payable                                 $ 4,852 $ 1,562  
Investor and redeemed | shares                                   103,200  
Redemption penalties                                 12,285    
Remaining put premium balance                                   $ 24,207  
Gain on extinguishment                                   24,207  
Conversion Price                                 450,204    
Equity Option [Member]                                      
Shareholders' Deficit (Textual)                                      
Recognized compensation expense                                 576,025 $ 1,539,188  
Total unrecognized compensation expense related to unvested common shares                         $ 33,636       33,636    
Accounts Payable [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares per share | $ / shares         $ 0.04                            
Sale of common shares, shares | shares         151,456                            
Sale of common shares, value         $ 6,058                            
Consulting Agreement [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares per share | $ / shares                 $ 0.04                    
Shares of grant restricted stock award of common shares | shares                 1,250,000                    
Value of grant restricted stock award of common shares                 $ 50,000                    
Stock-based professional fees                                 $ 50,000    
Employment Agreements [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares per share | $ / shares       $ 0.04                              
Shares of grant restricted stock award of common shares | shares       200,000                              
Value of grant restricted stock award of common shares       $ 8,000                              
Restricted Stock Award Agreements [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares per share | $ / shares               $ 0.04                      
Shares of grant restricted stock award of common shares | shares               6,750,000                      
Value of grant restricted stock award of common shares               $ 270,000                      
Percentage of restricted shares               100.00%                      
Investor [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares per share | $ / shares   $ 0.023     $ 0.04         $ 0.04                  
Sale of common shares, shares | shares   7,000,000     7,000,000         7,000,000                  
Sale of common shares, value   $ 161,000     $ 280,000         $ 280,000                  
Warrants [Member]                                      
Shareholders' Deficit (Textual)                                      
Exercise price | $ / shares                         $ 0.10       $ 0.10    
Warrant exercise price reduced | $ / shares                         $ 0.003       $ 0.003    
Warrant purchase, description                                 On March 30, 2020 and on April 23, 2020, in connection with Purchase Agreements with an accredited investor (See Note 6), the Company issued warrants to purchase an aggregate amount up to 288,750 shares of the Company's common stock (the "Warrants"). The Warrants were exercisable at any time on or after the date of the issuance and entitled this investor to purchase shares of the Company's common stock for a period of five years from the initial date the warrants become exercisable. Under the terms of the Warrants, the holder was entitled to exercise the Warrants to purchase up to 288,750 shares of the Company's common stock at an initial exercise price of $0.10, subject to adjustment as detailed in the Warrants. In connection with the issuance of the warrants, on the initial measurement date, the relative fair value of the warrants of $14,498 was recorded as a debt discount and an increase in paid-in capital (See Note 6).    
Preferred Stock                                      
Shareholders' Deficit (Textual)                                      
Accrued dividend payable                                 $ 1,740    
Non-vested, forfeitable common shares [Member]                                      
Shareholders' Deficit (Textual)                                      
Common shares issued for debt conversion, shares | shares 500,000                                    
Common shares issued for debt conversion, amount $ 6,500                                    
Shares conversion price 0.013                                    
Amount of common stock upon conversion                         $ 23,897 $ 12,800          
Shares of common stock upon conversion | shares                         23,896,800 12,800,000          
Issuance of common shares for services, shares | shares                         500,000 7,450,000 1,250,000        
Issuance of common shares for services, amount                         $ 500 $ 7,450 $ 1,250        
Stock-based professional fees $ 3,250                                    
Prepaid expenses $ 3,250                                    
2018 Long-term Incentive Plan [Member]                                      
Shareholders' Deficit (Textual)                                      
Aggregate shares of common stock issued without any minimum vesting period | shares                                 25,000,000    
Aggregate number of common stock issued under plan | shares                                 50,000,000    
Incentive stock options | shares                         11,445,698       11,445,698    
Description of options to acquire common stock                                 The exercise price of options granted under our 2018 Plan must at least be equal to the fair market value of the Company's common stock on the date of grant and the term of an option may not exceed ten years, except that with respect to an incentive stock option granted to any employee who owns more than 10% of the voting power of all classes of the Company's outstanding stock as of the grant date the term must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date.    
Restricted stock have been issued                         $ 23,700,000       $ 23,700,000    
Series A Preferred Stock [Member]                                      
Shareholders' Deficit (Textual)                                      
Shares designated | shares                         800,000       800,000   800,000
Preferred Stock par value | $ / shares                     $ 0.10 $ 0.10 $ 0.10       $ 0.10   $ 0.10
Preferred stock stated value | $ / shares                         $ 1.00       $ 1.00    
Preferred stock unregistered | shares                     211,200 211,200 154,800       154,800    
Preferred stock unregistered value                     $ 133,000 $ 133,000 $ 129,000       $ 129,000    
Cash proceeds                     127,000 127,000              
Net of fees                     6,000 6,000              
Amortization of debt discount                     $ 6,000 $ 6,000              
Debt premium to paid-in capital.                         49,543       49,543    
Stated value                         $ 211,200       $ 211,200    
Common shares per share | $ / shares                     $ 0.833 $ 0.833 $ 0.833       $ 0.833    
Accrued dividends                         $ 4,224       $ 4,224    
Aggregate premium                         $ 0       $ 0    
Series C Preferred Stock [Member]                                      
Shareholders' Deficit (Textual)                                      
Shares designated | shares                         100,000       100,000   100,000
Preferred Stock par value | $ / shares             $ 0.10           $ 0.10       $ 0.10   $ 0.10
Preferred stock stated value | $ / shares                         $ 100.00       $ 100.00    
Preferred Stock dividend Rate             2.00%                   4.00%    
Preferred stock dividend increased                                 22.00%    
Conversion price converted into market price                                 81.00%    
Market price representing at discount rate                                 19.00%    
Debt premium charge to interest expenses                                 $ 42,553    
Preferred stock unregistered value                         $ 630,000       630,000    
Cash proceeds                                 120,000    
Net of fees                                 9,000    
Amortization of debt discount                                 9,000    
Amortization of discount charged to interest expense                                 14,333    
Amount of common stock upon conversion                                 $ 211,200    
Shares of common stock upon conversion | shares                                 16,132,701    
Interest expense                                 $ 126,423    
Description of options to acquire common stock                                 The Company issued 16,132,701 shares its common stock upon the conversion of 211,200 shares of Series A preferred with a stated redemption value of $211,200 and related accrued dividends payable of $4,224. The conversion price was based on contractual terms of the related Series A preferred shares. Upon conversion, the Company reclassified put premium of $49,543 to paid-in capital.    
Purchase of shares | shares           6,300                     6,300    
Designations established share | shares             100,000                        
Series B Preferred Stock [Member]                                      
Shareholders' Deficit (Textual)                                      
Shares designated | shares           100,000             100,000       100,000   100,000
Preferred Stock par value | $ / shares           $ 0.10             $ 0.10       $ 0.10   $ 0.10
Preferred Stock dividend Rate           2.00%                          
Stated value           $ 1,000                          
Accrued dividends                         $ 1,055       $ 1,055    
Series A preferred stock balance                         109,740       109,740    
Liquidation value                         $ 630,000       630,000    
Conversion of principal balance                                 631,055    
Stock option, description           The Series B is convertible at the option of a holder or if the closing price of the common stock exceeds 400% of the Conversion Price for a period of twenty consecutive trading days, at the option of the Company. Conversion Price means a price per share of the common stock equal to 100% of the lowest daily volume weighted average price of the common stock during the two years preceding or subsequent two years following the Issuance Date, subject to adjustment as otherwise provided in the Certificate of Designations (the "Conversion Price").                          
Accrued dividend payable                                 $ 1,740    
Convertible Preferred Stock [Member]                                      
Shareholders' Deficit (Textual)                                      
Settlement of accrued compensation | shares           108